Phase 2 Trial Using rhDNase to Reduce Mortality in COVID-19 Patients With Respiratory Failure

NCT04445285 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

44

Enrollment

OTHER

Sponsor class

Conditions

Covid19

Interventions

DRUG: Pulmozyme/ Recombinant human deoxyribonuclease (rh-DNase)
DRUG: 0.9%sodium chloride

Sponsor

Jon Simmons

Collaborators

[object Object]